Mechanisms by Which Interferon Potentiates Chemotherapy

References

• Wadler S., Schwartz E L, Goldman M. Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colon cancer. J Clin Oncol 1989; 7: 1769–1775
   PubMed Web of Science ®Google Scholar
• Wadler S, Lembersky B, Atkins M. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 1991; 9: 1806–1810
   PubMed Web of Science ®Google Scholar
• Falkson C I, Falkson G, Falkson H C. Improved results with the addition of interferon alfa-2b to decarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1405–1408
   Google Scholar
• Mulder N H, Willemse P HB, Scharaffordt K H. Dacarbazine (DTIC) and human recombinant interferon alpha-2a (Roferon) in the treatment of disseminated malignant melanoma. Br J Cancer 1990; 62: 1006–1007
   PubMed Web of Science ®Google Scholar
• Baron S, Tyring S K, Fleischmann W R. The interfer-ons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375–1383
   PubMed Web of Science ®Google Scholar
• Lin S L, Kikuchi T., Pledger W J, Tamm I. Interferon inhibits the establishment of competence in G0/S-phase transition. Science 1986; 233: 356–359
   PubMed Web of Science ®Google Scholar
• Einat M, Resnitzky D, Kimchi A. Close link between reduction of c-myc expression by interferon and G0/GI arrest. Nature 1985; 313: 597–600
   PubMed Web of Science ®Google Scholar
• Tamm I, Jasny B R, Pfeffer L M. Antiproliferative action of in-terferons. Mechanisms of Interferon Actions, Vol II, LM Pfeffer. CRC Press, Boca Raton, FL 1987; 25–57
   Google Scholar
• Neefe JR., Sullivan J E, Ayoob M. Augmented immunity in cancer patients treated with a-interferon. Cancer Res 1985; 45: 874–878
   PubMed Web of Science ®Google Scholar
• Gresser I, Bourali C, Levy J P. Increased survival in mice innoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci USA 1969; 635–57
   Google Scholar
• Sklarin N T, Chahinian A P, Feur E J. Augmentation of cis diamminedichloroplatinum (II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 1988; 18: 64–67
   Google Scholar
• Carmichael J, Fergusson RJ., Wolf C R. Augmentation of cytotoxicity by human a-interferons in human non-small cell lung cancer xenografts. Cancer Res 1986; 46: 4916–4920
   PubMed Web of Science ®Google Scholar
• Welander C E. Overview of preclinical and clinical studies of interferon alfa-2b in combination with cytotoxic drugs. Investi-gational New Drugs 1987; 5: 47–59, Suppl
   Google Scholar
• Von Hoff D. In vitro data supporting interferon plus cytotoxic agent combinations. Semin Oncol 1991; 18: 50–61, Suppl 7
   PubMedGoogle Scholar
• Wadler S, Wersto R, Weinberg V. Interaction of fluorouracil and interferon in human colon cancer cell lines: Cytotoxic and cytokinetic effects. Cancer Res 1990; 50: 5735–5784
   PubMed Web of Science ®Google Scholar
• Wadler S, Schwartz E L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990; 50: 3473–3486
   PubMed Web of Science ®Google Scholar
• Stolfi R L, Martin D S, Sawyer R C, Spiegelman S. Modupation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid. Cancer Res 1983; 43: 561–566
   PubMed Web of Science ®Google Scholar
• Balkwill F R, Mowshowitz S., Seilman S S. Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. Cancer Res 1984; 44: 5249–5255
   PubMed Web of Science ®Google Scholar
• Morikawa K, Fan D, Denkins Y M. Mechanisms of combined effects of gamma interferon and 5-fluorouracil on human colon cancers implanted into nude mice. Cancer Res 1989; 49: 799–805
   PubMed Web of Science ®Google Scholar
• Neefe J R, Glass J. Abrogation of interferon-induced resistance to interferon activated major histocompatibility complex-unrcstricted killers by treatment of a melanoma cell line with 5-fluorouracil. Cancer Res 1991; 51: 3159–3163
   PubMed Web of Science ®Google Scholar
• Grem J L. Fluorinated pyrimidines. Cancer Chemotherapy. Principles and Practice, BA Chabner, JM Collins. Lippincott, Philadelphia 1990; 183–188
   Google Scholar
• Elias L, Sandoval J M. Interferon effects upon tluorouracil metabolism by HL-60 cells. Biochem Biophys Rcs Commun 1989; 163: 367–874
   Google Scholar
• Chu E, Zinn S, Boarman D, Allegra C. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990; 50: 5834–5840
   PubMed Web of Science ®Google Scholar
• Schwartz E L, Hoffman M., O'Connor C, Wadler J. S. Stimulation of S-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Rea Comniun 1992; 182: 1232–1239
   PubMed Web of Science ®Google Scholar
• Lindley C, Bernard S, Gavigan M. Interferon-alpha increases 5-fluorouracil levels 64 fold within I hour: Results of a phase 1 study. J Interferon Res 1990; 10: 132, Suppl
   Google Scholar
• Grem J L, McAtel N, Murphy R. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leuco-vorin in metastatic gastrointestinal carcinoma. J Clin Oncol 1991; 9: 1811–1820
   PubMed Web of Science ®Google Scholar
• Danhauser L, Gilchrist T, Freimann J. Effect of recombinant interferon-α 2b on the plasma pharmacokinetics of tluorouracil in patients with advanced cancer. Proc Am Assoc Cancer Res 1991; 32: 176
   Google Scholar
• Schuller J., Czejka M, Miksche M. Influence of interferon α 2b (IFN) ± leucovorin (LV) on pharmacokinetics (PK) of 5-fluorouracil. Proc Am Soc Clin Oncol 1991; 10: 98
   Google Scholar